Exploring synaptic pathways in traumatic brain injury: a cross-phenotype genomics approach.

GENOMICS SYNAPTIC LOSS AND DEAFFERENTATION TRAUMATIC BRAIN INJURY

Journal

Journal of neurotrauma
ISSN: 1557-9042
Titre abrégé: J Neurotrauma
Pays: United States
ID NLM: 8811626

Informations de publication

Date de publication:
12 Sep 2024
Historique:
medline: 12 9 2024
pubmed: 12 9 2024
entrez: 12 9 2024
Statut: aheadofprint

Résumé

Traumatic brain injury (TBI), a global leading cause of mortality and disability, lacks effective treatments to enhance recovery. Synaptic remodeling has been postulated as one mechanism that influences outcomes after TBI. We sought to investigate whether common mechanisms affecting synapse maintenance are shared between TBI and other neuropsychiatric conditions using pathway enrichment tools and genome-wide genotype data, with the goal of highlighting novel treatment targets. We leveraged an integrative approach, combining data from Genome-Wide Association Studies (GWAS) with pathway and gene-set enrichment analyses. Literature review-based and Reactome database-driven approaches were combined to identify synapse-related pathways of interest in TBI outcome, and to assess for shared associations with conditions in which synapse-related pathobiological mechanisms have been implicated, including Alzheimer's disease (AD), schizophrenia (SCZ), major depressive disorder (MDD), post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Gene and pathway-level enrichment analyses were conducted using MAGMA and its extensions, e- and H-MAGMA, followed by Mendelian Randomization (MR) to investigate potential causal associations. Of the 98 pathways tested, 32 were significantly enriched in the included conditions. In TBI outcome, we identified significant enrichment in five pathways: "Serotonin clearance from the synaptic cleft" (p-value = 0.0001), "Presynaptic nicotinic acetylcholine receptors" (p-value = 0.0003), "Postsynaptic nicotinic acetylcholine receptors" (p-value = 0.0003), "Highly sodium permeable postsynaptic acetylcholine nicotinic receptors" (p-value = 0.0001), and "Acetylcholine binding and downstream events" pathways (p-value = 0.0003). These associations highlight potential involvement of the cholinergic and serotonergic systems in post-TBI recovery. Three of those pathways were shared between TBI and schizophrenia, suggesting possible pathophysiologic commonalities. In this study we utilize comparative and integrative genomic approaches across brain conditions that share synaptic mechanisms to explore the pathophysiology of TBI outcome. Our results implicate associations between TBI outcome and synaptic pathways as well as pathobiologic overlap with other neuropsychiatric diseases.

Identifiants

pubmed: 39264867
doi: 10.1089/neu.2024.0153
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Savvina Prapiadou (S)

Brigham and Women's Hospital, Neurology, 75 Francis St, Boston, Massachusetts, United States, 02115; sprapiadou@mgh.harvard.edu.

Ernst Mayerhofer (E)

Massachusetts General Hospital Center for Genomic Medicine, Boston, Massachusetts, United States.
Broad Institute, Cambridge, Massachusetts, United States.
Massachusetts General Hospital McCance Center for Brain Health , Boston, Massachusetts, United States; ernst.mayerhofer@gmail.com.

Marios K Georgakis (MK)

Broad Institute, Cambridge, Massachusetts, United States.
Ludwig Maximilian University of Munich, Institute for Stroke and Dementia Research (ISD), Munchen, Bayern, Germany; Marios.Georgakis@med.uni-muenchen.de.

Mart Kals (M)

University of Tartu, Estonian Genome Center, Institute of Genomics, Tartu, Tartumaa, Estonia; mart.kals@ut.ee.

Farid Radmanesh (F)

Brigham and Women's Hospital, Department of Neurology , Boston, Massachusetts, United States.
The University of New Mexico - Albuquerque, Department of Neurology, Division of Neurocritical Care, Albuquerque, New Mexico, United States; farid.radmanesh@gmail.com.

Saef Izzy (S)

Brigham & Women's Hospital, Harvard Medical School, Neurology, Boston, Massachusetts, United States; sizzy@bwh.harvard.edu.

Sylvia Richardson (S)

University of Cambridge School of Clinical Medicine, MRC Biostatistics Unit, Robinson Way, Forvie Site, Cambridge, United Kingdom of Great Britain and Northern Ireland, CB20SR.
University of Cambridge, MRC Biostatistics Unit, Cambridge, United Kingdom of Great Britain and Northern Ireland, CB20SR; sylvia.richardson@mrc-bsu.cam.ac.uk.

David O Okonkwo (DO)

University of Pittsburgh Department of Neurological Surgery, Neurosurgery, Pittsburgh, Pennsylvania, United States; okonkwodo@upmc.edu.

Ava M Puccio (AM)

University of Pittsburgh Department of Neurological Surgery, B400-PUH, 200 Lothrop Street, Pittsburgh, Pennsylvania, United States, 15213-2536; puccioAM@upmc.edu.

Nancy Temkin (N)

University of Washington, Neurological Surgery, Box 359924, 325 9th Ave, Seattle, Washington, United States, 98104; temkin@uw.edu.

Aarno Palotie (A)

Massachusetts General Hospital Center for Genomic Medicine, Boston, Massachusetts, United States.
Broad Institute, Cambridge, Massachusetts, United States.
University of Helsinki Institute for Molecular Medicine Finland, Helsinki, Uusimaa, Finland; aarno.palotie@helsinki.fi.

Samuli Ripatti (S)

Broad Institute, Cambridge, Massachusetts, United States.
University of Helsinki Institute for Molecular Medicine Finland, Helsinki, Uusimaa, Finland.
University of Helsinki Department of Public Health, Helsinki, Uusimaa, Finland; samuli.ripatti@helsinki.fi.

Ramon Diaz-Arrastia (R)

University of Pennsylvania, Neurology, Penn Presbyterian Medical Center, 51 North 39th Street, Andrew Mutch Bldg., Room 409, Philadelphia, Pennsylvania, United States, 19104; Ramon.Diaz-Arrastia@pennmedicine.upenn.edu.

Murray B Stein (MB)

University of California San Diego Department of Psychiatry, La Jolla, California, United States; mstein@health.ucsd.edu.

Geoffrey T Manley (GT)

University of California San Francisco, Neurosurgery, 1001 Potrero Ave, SF, CA, San Francisco, California, United States, 94110.
UCSF Weill Institute for Neurosciences, San Francisco, California, United States; ManleyG@ucsf.edu.

David Menon (D)

University of Cambridge, Head, Division of Anaesthesia, Box 93, Addenbrooke's Hospital, Hills Road, Cambridge, Cambs, United Kingdom of Great Britain and Northern Ireland, CB2 2QQ; dkm13@cam.ac.uk.

Jonathan Rosand (J)

Massachusetts General Hospital Center for Genomic Medicine, Boston, Massachusetts, United States.
Broad Institute, Cambridge, Massachusetts, United States.
Massachusetts General Hospital McCance Center for Brain Health, Boston, Massachusetts, United States; jrosand@partners.org.

Livia Parodi (L)

Massachusetts General Hospital Center for Genomic Medicine, Boston, Massachusetts, United States.
Broad Institute, Cambridge, Massachusetts, United States.
Massachusetts General Hospital McCance Center for Brain Health , Boston, Massachusetts, United States.
Brigham and Women's Hospital, Department of Neurology, Boston, Massachusetts, United States; parodi.livia@outlook.com.

Christopher D Anderson (CD)

Massachusetts General Hospital Center for Genomic Medicine, Boston, Massachusetts, United States.
Broad Institute, Cambridge, Massachusetts, United States.
Massachusetts General Hospital McCance Center for Brain Health , Boston, Massachusetts, United States.
Brigham and Women's Hospital, Department of Neurology, Boston, Massachusetts, United States; cdanderson@mgb.org.

Classifications MeSH